Orexo AB (STO: ORX, OTCQX: ORXOY), a Sweden-based pharmaceutical company, announced today the initiation of a new clinical study for its intranasal medication, OX640, targeting patients with allergic rhinitis. This study marks an important step in Orexo’s ongoing commitment to addressing allergy-related conditions, providing an innovative, fast-acting treatment option for people affected by nasal allergies.
OX640 is an investigational drug formulated as a nasal spray, designed to provide rapid relief for people suffering from allergic rhinitis, a condition affecting millions worldwide. Allergic rhinitis, commonly known as hay fever, is an allergic reaction in the nasal passages triggered by exposure to allergens such as pollen, dust, or pet dander. Symptoms, including sneezing, nasal congestion, runny nose, and itching, can significantly affect quality of life, particularly during allergy seasons.
Orexo’s OX640 spray is designed to quickly and effectively address these symptoms, offering a fast-acting, non-invasive alternative to traditional oral and injectable treatments. The new study aims to evaluate the drug’s safety, efficacy, and ability to relieve symptoms in participants with allergic rhinitis.
The study will enroll participants diagnosed with allergic rhinitis to assess the therapeutic effects of OX640 on the severity of their symptoms. Participants will receive OX640 through nasal spray applications over a defined treatment period, with Orexo’s research team carefully monitoring safety outcomes, symptom relief, and any potential adverse effects. Additionally, the study will assess the onset of action, aiming to provide insights into how quickly OX640 can alleviate symptoms.
Orexo has highlighted the importance of developing a medication that can deliver immediate relief for allergy sufferers, many of whom require rapid intervention to manage symptoms that can arise suddenly. With this trial, the company seeks to validate the potential for OX640 to become a reliable, fast-acting treatment option for allergic rhinitis.
With the initiation of this study, Orexo advances its strategic goal to expand into respiratory and allergy-related conditions, diversifying its product pipeline beyond its established work in addiction medicine. The success of OX640 could position Orexo as a competitive player in the allergic rhinitis market, particularly given the rising global demand for effective, rapid allergy treatments.
Robert Rönn, SVP and Head of R&D, said: “Anaphylaxis is a serious and life-threatening condition, making it essential to ensure that OX640 remains effective even in the presence of nasal allergic symptoms. The study addresses key development and regulatory requirements and is an important step in advancing the project towards regulatory approval. The performance of OX640 under allergic rhinitis conditions has also been requested in many discussions with health care providers and with potential partners.”
If the study produces favorable results, Orexo plans to pursue further clinical trials, with the ultimate goal of obtaining regulatory approval for OX640 in multiple markets. The company hopes that OX640 will provide a competitive alternative for allergic rhinitis treatment, with faster onset of action than conventional antihistamines and corticosteroids.
Orexo’s commitment to developing innovative solutions for complex conditions has driven its focus on respiratory health and fast-acting treatments. This study initiation is a crucial step forward for the company, and as results emerge, Orexo will likely gain critical insights into OX640’s role in the future of allergy management.
Orexo AB’s launch of the OX640 study marks a pivotal development in allergy treatment research, aimed at providing rapid relief for patients with allergic rhinitis. The study is expected to conclude in 2024, with results anticipated in early 2025.
